Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021
FREMONT, Calif. and WALTHAM, Mass., April 12, 2021 /PRNewswire/ -- Ardelyx Inc.. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it will present a poster highlighting data from NORMALIZE, an ongoing Phase 4 trial designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve normal serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis at the ISN World Congress of Nephrology 2021, which will take place virtually April 16-19, 2021.
Details on Ardelyx's poster:
Abstract Title: A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination with Sevelamer to Achieve Normal Serum Phosphorus in Patients with CKD on Dialysis (NORMALIZE)
For more information on these and other abstracts, please visit the ISN World Congress of Nephrology 2021 website.
About Ardelyx, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-announces-upcoming-data-presentation-at-isn-world-congress-of-nephrology-2021-301266431.html
Company Codes: NASDAQ-NMS:ARDX